2016
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters 2016, 649: 147-155. PMID: 27916636, PMCID: PMC5482215, DOI: 10.1016/j.neulet.2016.11.064.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychiatric disordersStress-related psychiatric disordersAlternative pharmacologic treatmentsPutative neurobiological underpinningsGlutamate-modulating agentsTrauma-related disordersGlutamatergic abnormalitiesGlutamate dysregulationPharmacologic treatmentPharmacologic interventionsGlutamatergic functionGlutamate neurotransmissionMillions of individualsHuman studiesCardinal featuresStress disorderDisordersNeurobiological underpinningsRelated future directionsEvidenceChronicDysfunctionNeurotransmissionSubject data
2003
Toward early pharmacological posttraumatic stress intervention
Morgan CA, Krystal JH, Southwick SM. Toward early pharmacological posttraumatic stress intervention. Biological Psychiatry 2003, 53: 834-843. PMID: 12725976, DOI: 10.1016/s0006-3223(03)00116-1.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderExtreme psychological traumaStress-related symptomsIntrusive memoriesPsychological processingExtreme arousalTrauma survivorsPsychological traumaStress disorderStress interventionsAcute aftermathExtreme stressPharmacologic interventionsAdaptive roleEffective pharmacologic interventionsPotential pharmacologic interventionsInterventionTransient symptomsImmediate aftermathArousalEmpirical dataEarly symptomsMemorySymptomsTrauma